US FDA declines to approve Capricor's Duchenne treatment citing unreliable trial data; shares slump - Reuters

Reuters

US FDA declines to approve Capricor's Duchenne treatment citing unreliable trial data; shares slump Reuters

US FDA declines to approve Capricor's Duchenne treatment citing unreliable trial data; shares slump Reuters

Ver fuente original → ← Volver a noticias